Maximo F. Nougues, Chief Financial Officer of Breathe Biotechnology, Inc. (NASDAQ: ), a profitable biotechnology company currently valued at $144 million with a P/E ratio of 6.14, recently sold 10,227 shares of common stock. The transaction, which took place on January 2, 2025, was made at a limited price of $3.1517 per share, resulting in a total value of approximately $32,232. Following this sale, Nogues retains ownership of 152,295 shares in the company. The sale was part of a business plan previously established under Rule 10b5-1, which was approved on December 14, 2020. InvestingPro analysis, PBYI is currently trading below its Fair Value, with a GREAT score for financial health. InvestingPro subscribers have access to 6 additional key insights and a comprehensive Pro Research Report, part of their 1,400+ US stocks.
In other recent news, Puma (OTC:) Biotechnology has made progress in its operations. The company's third quarter revenue in 2024 saw a significant increase, reaching $80.5 million, up from $51.6 million in the same period last year. This growth was primarily driven by sales of NERLYNX, Puma's flagship product, and a marked increase in royalties due to its performance in the Chinese market.
Puma Biotechnology's profile was recently bolstered by support from the National Comprehensive Cancer Network (NCCN), which is updating its Clinical Practice Guidelines in Oncology for Cervical Cancer to include Puma's Nerlynx as a treatment option. This recommendation is specific to patients with HER2-mutated tumors to use Nerlynx in recurrent or metastatic disease as a second line or subsequent treatment.
According to HC Wainwright, this new development is likely to have a positive impact on Nerlynx sales, although no changes to sales forecasts have been made at this time. Current estimates for Nerlynx net sales stand at $46.4 million in the fourth quarter of 2024, with projected product sales of $187.2 million for the full year of 2024 and $195.3 million in 2025. These are recent developments that provide a glimpse into Puma Biotechnology's ongoing operations and future prospects.
This article is powered by AI and updated by an editor. For more information see our T&C.